Beyond first-line therapy: efficacy and safety outcomes of continuing immunotherapy in extensive stage small cell lung cancer after PD-L1 inhibitor progression
In patients with ES-SCLC who received first-line PD-L1 inhibitors, continuing IBP extended second-line survival without increasing adverse events (AEs). A more pronounced OS benefit with IBP was noted within specific patient subgroups.
Authors
- Jianfeng Peng (ORCID: https://orcid.org/0000-0002-1379-4773)
- Ran Gao (ORCID: https://orcid.org/0000-0001-8712-429X)
- Xiangjiao Meng (ORCID: https://orcid.org/0000-0003-2737-5905)
- Xiaomei Liu (ORCID: https://orcid.org/0000-0003-0934-7249)
- Yimeng Wang (ORCID: https://orcid.org/0000-0003-0790-1277)
- Zhaoqin Huang
- X. Zhai (ORCID: https://orcid.org/0000-0003-2821-6930)
- Peizhu Wu
Institutions
- Shandong First Medical University (CN)
- Jinzhou Medical University (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1016/j.tranon.2024.102249
- Citations
- 4
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Key Technology Research and Development Program of Shandong